-
Oct 3, 2024 | 
preprints.org | Mauro Scimia |Francesco Pepe |Gianluca Russo |Umberto Malapelle
Preprint Article Version 1 This version is not peer-reviewed Version 1 : Received: 2 October 2024 / Approved: 3 October 2024 / Online: 3 October 2024 (12:30:08 CEST) Scimia, M.; Pepe, F.; Russo, G.; Malapelle, U.; Scimia, S.; Alfieri, A.; Olivieri, V.; Chuang, R.; Tanaka, H.; Sha, M.; Chen, D.; Shen, S.; Scimone, C.; Palumbo, L.; Gavrilov, Y.; Edelstein, S.; Bianco, M. A.; Troncone, G.
-
Sep 14, 2024 | 
dailyreporter.esmo.org | Umberto Malapelle
Despite the recent improvements in the management of lung cancer, the vast majority of patients still experience poor clinical outcomes mainly due to challenges in early detection, the high risk of metastasis, and the development of resistance to multiple therapies. However, great strides have been made with the introduction of liquid biopsy in the diagnostic algorithm for this population (J Thorac Oncol. 2021;16:1647–1662; Lung Cancer. 2022;172:53–64).
-
May 15, 2024 | 
nature.com | Umberto Malapelle |Natasha Leighl |Dov Hershkovitz
AbstractNon-small cell lung cancer is a heterogeneous disease and molecular characterisation plays an important role in its clinical management. Next-generation sequencing-based panel testing enables many molecular alterations to be interrogated simultaneously, allowing for comprehensive identification of actionable oncogenic drivers (and co-mutations) and appropriate matching of patients with targeted therapies.
-
Mar 29, 2024 | 
mdpi.com | Denis Horgan |Umberto Malapelle |Nicola Normanno |Ettore Capoluongo
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Feb 29, 2024 | 00011-5/fulltext&sz=64)
thelancet.com | Umberto Malapelle |Silvia Novello
In the era of precision oncology, a rapidly increasing number of predictive biomarkers have been routinely implemented to define the advanced non-small cell lung cancer (NSCLC) patients’ treatment decision making process.
-
Jan 19, 2024 | 
mdpi.com | Denis Horgan |Umberto Malapelle |Nicola Normanno |Ettore Capoluongo
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
-
Oct 27, 2023 | 
mdpi.com | Denis Horgan |Umberto Malapelle |Nicola Normanno |Ettore Capoluongo
1. IntroductionCancer remains one of the most significant health challenges in Europe and beyond. In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it [1]; worldwide, it accounted for nearly 10 million deaths in 2020, or nearly one in six deaths [2]. Incidence continues to vary across the European Union (Figure 1), from 458/100,000 in Bulgaria to 718/100,000 in Ireland in 2019 [3].
-
Oct 18, 2023 | 
frontiersin.org | Umberto Malapelle |Isabel Soto-Cruz
IntroductionCervical cancer (CC) is one of the most common types of carcinomas among women globally, after only breast, colorectal, and lung cancer (1). Thus, identification of prognostic biomarkers or therapeutic targets for the management of CC is strongly warranted.
-
Oct 14, 2023 | 
sciencedirect.com | Umberto Malapelle |Christian Rolfo |Albert Abad |... Santiago Viteri
The Journal of Liquid Biopsy aims to cover the research insight into the molecular pathways analyzed by using liquid biopsy-based biomarkers (cfDNA, ctDNA, miRNA, CTC, extracellular vesicles, protein, etc.) and their relative clinical implication. An integrated approach that includes molecular findings, technical aspects, and clinical data is encouraged to provide a comprehensive view of liquid biopsy.
-
Oct 3, 2023 | 
frontiersin.org | Maria Grazia |Umberto Malapelle |Pilar Ramos |Del Ponte Women’s
1 IntroductionEpithelial ovarian cancer (EOC) is the most common lethal malignancy among gynecological cancers with a poor outcome due to late diagnosis caused by a lack of early signs and symptoms of this disease (1). The standard treatment for EOCs is cytoreductive surgery and platinum-based chemotherapy.
